Intus Biosciences Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2M
- Investors
-
5
Intus Biosciences General Information
Description
Developer of a machine learning-driven analysis platform designed to merge patented foundational science and sequencing technology. The company's platform allows the microbiome to be as critical to healthcare to overcome the challenges that hinder existing methods and provides unprecedented insights to physicians and patients, enabling clients to identify bacteria and deliver answers about the microbiome, with detail, accuracy, and scale.
Contact Information
Website
www.intusbio.comCorporate Office
- 400 Farmington Avenue
- CB119
- Farmington, CT 06032
- United States
Corporate Office
- 400 Farmington Avenue
- CB119
- Farmington, CT 06032
- United States
Intus Biosciences Timeline
Intus Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC | 16-Jul-2024 | $2M | 000.00 | Completed | Generating Revenue | |
| 13. Later Stage VC | 16-Nov-2022 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 12. Later Stage VC | 21-Jan-2022 | 00.00 | 00.000 | Completed | Generating Revenue | |
| 11. Later Stage VC | 07-Jan-2021 | 00000 | 00.000 | Completed | Generating Revenue | |
| 10. Seed Round | 27-May-2020 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 9. Debt - PPP | 07-Apr-2020 | 00.000 | Completed | Generating Revenue | ||
| 8. Seed Round | 14-Feb-2018 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 7. Grant | 01-Apr-2017 | 00000 | 00000 | Completed | Generating Revenue | |
| 6. Seed Round | 31-May-2016 | $540K | $835K | Completed | Generating Revenue | |
| 5. Debt - General | 06-May-2016 | $295K | Completed | Generating Revenue |
Intus Biosciences Comparisons
Industry
Financing
Details
000000
000000
Intus Biosciences Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nuanced Health | Venture Capital-Backed | Los Angeles, CA | 00 | 000 | 000000000000 | 000 |
| Theriva Biologics | Corporation | Rockville, MD | 00 | 000.00 | 000000000 | 000.00 |
| Rheos Medicines | Venture Capital-Backed | Cambridge, MA | 00 | 0000 | 00000000000 | 0000 |
| Persephone (Drug Discovery) | Venture Capital-Backed | San Diego, CA | 00 | 000.00 | 000000000 | 000.00 |
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 0000000000 | 00000 |
Intus Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Intus Biosciences Patents
Intus Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3788168-A1 | Multiple specific/nonspecific primers for pcr of a complex gene pool | Pending | 04-May-2018 | 0000000000 | |
| US-20190352712-A1 | Multiple specific/nonspecific primers for pcr of a complex gene pool | Pending | 04-May-2018 | 0000000000 | |
| EP-3788168-A4 | Multiple specific/nonspecific primers for pcr of a complex gene pool | Pending | 04-May-2018 | 0000000000 | 0 |
| AU-2019263364-A1 | Multiple specific/nonspecific primers for pcr of a complex gene pool | Pending | 04-May-2018 | 0000000000 | |
| CA-3095755-A1 | Multiple specific/nonspecific primers for pcr of a complex gene pool | Pending | 04-May-2018 | C12Q1/6851 |
Intus Biosciences Executive Team (6)
| Name | Title | Board Seat |
|---|---|---|
| Paul Denslow | Co-Founder, Chief Executive Officer & Chairman | |
| Mark Driscoll Ph.D | Co-Founder, Chief Scientific Officer & Board Member | |
| Peter Lee | Head of Corporate Strategy | |
| Alan Kersey | Advisor | |
| William McKenzie | Advisor |
Intus Biosciences Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Mendelson | Self | Board Member | 000 0000 |
| Frank Marco JD | Wiggin and Dana | Board Member | 000 0000 |
| Mark Driscoll Ph.D | Intus Biosciences | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
| Matt Watson | Self | Board Member | 000 0000 |
| Paul Denslow | Intus Biosciences | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
Intus Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Intus Biosciences Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aimers Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
| VC23 Investors | Venture Capital | Minority | 000 0000 | 000000 0 |
| UConn Innovation Fund | Venture Capital | Minority | 000 0000 | 000000 0 |
| National Institute on Drug Abuse (NIDA) | Government | 000 0000 | 000000 0 | |
| Connecticut Innovations | Venture Capital | Minority | 000 0000 | 000000 0 |
Intus Biosciences Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pattern Genomics | 15-Jun-2023 | 0000000000 | Media and Information Services (B2B) |
Intus Biosciences FAQs
-
When was Intus Biosciences founded?
Intus Biosciences was founded in 2014.
-
Who is the founder of Intus Biosciences?
Thomas Jarvie Ph.D, Paul Denslow, and Mark Driscoll Ph.D are the founders of Intus Biosciences.
-
Who is the CEO of Intus Biosciences?
Paul Denslow is the CEO of Intus Biosciences.
-
Where is Intus Biosciences headquartered?
Intus Biosciences is headquartered in Farmington, CT.
-
What is the size of Intus Biosciences?
Intus Biosciences has 12 total employees.
-
What industry is Intus Biosciences in?
Intus Biosciences’s primary industry is Biotechnology.
-
Is Intus Biosciences a private or public company?
Intus Biosciences is a Private company.
-
What is Intus Biosciences’s current revenue?
The current revenue for Intus Biosciences is 000000.
-
How much funding has Intus Biosciences raised over time?
Intus Biosciences has raised $11.3M.
-
Who are Intus Biosciences’s investors?
Aimers Venture Partners, VC23 Investors, UConn Innovation Fund, National Institute on Drug Abuse (NIDA), and Connecticut Innovations have invested in Intus Biosciences.
-
Who are Intus Biosciences’s competitors?
Nuanced Health, Theriva Biologics, Rheos Medicines, Persephone (Drug Discovery), and Vedanta Biosciences are some of the 25 competitors of Intus Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
